Zai Lab PE Ratio 2016-2021 | ZLAB

Current and historical p/e ratio for Zai Lab (ZLAB) from 2016 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Zai Lab PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Zai Lab PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 100.75 0.00
2021-06-30 176.99 $-4.40 0.00
2021-03-31 133.43 $-2.64 0.00
2020-12-31 135.34 0 0.00
2020-06-30 82.13 0 0.00
2020-03-31 51.48 0 0.00
2019-12-31 41.59 0 0.00
2019-09-30 32.35 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $9.612B $0.049B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76